CDKN2A and chordoma: The absence of therapeutic options for patients with chordoma makes this observation clinically significant as p16 loss has been shown to sensitise to CDK4/6 inhibitors 15, 19, 20, making expression of p16 a potential biomarker for patient stratification and prognosis.